FDA investigates fatal case linked to rare blood disorder drug Adzynma
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The move is expected to be crucial during health crises
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The initiative aims to connect startups and tech companies with its business units,
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Subscribe To Our Newsletter & Stay Updated